CIAKESO@EC2602A(15667.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
CIAKESO@EC2602A
15667.HK
News
View More

Top 5 HK Stock Gainers/Losers (>100B) (1.21)

GIGADEVICE(03986) rose 6.14%, with a trading turnover 758.6 Million HKD, and a year-to-date rose 100.5%. GANFENGLITHIUM(01772) rose 5.54%, with a trading turnover 926.9 Million HKD, and a year-to-date rose 26.5%. ANTA SPORTS(02020) fell 4.18%, with a trading turnover 2.8 Billion HKD, and a year-to-date fell 1.8%. NTES-S(09999) fell 3.7%, with a trading turnover 2.0 Billion HKD, and a year-to-date fell 3.1%.

Top Gainers & Losers·
HK
03986
-2.79%
HK
01772
-0.79%
HK
01787
+4.51%
Top Gainers & Losers·
HK
03986
-2.79%
HK
01772
-0.79%
HK
01787
+4.51%

Akeso sNDA for Gumokimab in Ankylosing Spondylitis Accepted for NMPA Review

Akeso Inc. announced that the National Medical Products Administration (NMPA) in China has accepted the supplemental New Drug Application (sNDA) for gumokimab (AK111), a monoclonal antibody for treating active ankylosing spondylitis. This is the second indication for gumokimab to receive NDA review, following its acceptance for psoriasis. The NDA acceptance is based on positive results from a Phase III clinical trial showing significant improvements in symptoms and quality of life for patients with the condition.

Reuters·
HK
09926
-3.78%
Reuters·
HK
09926
-3.78%

In "Big Banks," CICC predicts that Zijin Mining, BeiGene, property insurance, and Akeso may "replace" Hang Seng Bank in Standard Chartered's "blue" category

The CICC report pointed out that the Hang Seng Index Company will announce the results of its annual review on February 13, which may affect major indices such as the Hang Seng, the China Enterprises Index, and the Hang Seng Tech Index. It is expected that Zijin Mining International, Yum China, and BeiGene will meet the inclusion criteria, while Hang Seng Bank may be delisted and replaced by other companies. The report emphasizes that, despite quantitative standards, the actual results may differ from the forecasts

AASTOCKS·
HK
09926
-3.78%
HK
00011
0.00%
AASTOCKS·
HK
09926
-3.78%
HK
00011
0.00%

Akeso, Inc. Announces Presentation of Real-World Study At the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Akeso, Inc. announced a real-world study presentation at the 2026 ASCO GI Symposium, comparing cadonilimab plus chemotherapy to a PD-1 inhibitor plus chemotherapy for advanced gastric cancer treatment. Results showed significant improvements in overall survival (OS) and progression-free survival (PFS) for the cadonilimab regimen. The study addresses the unmet clinical need for PD-L1-low or negative patients, as current PD-1 therapies are limited to PD-L1-positive cases. Akeso is advancing Phase III studies for cadonilimab, with FDA approval for the COMPASSION-37 study expected by late 2025.

marketscreener·
HK
09926
-3.78%
marketscreener·
HK
09926
-3.78%

Real-world study at ASCO GI shows Cadonilimab beats PD-1 inhibitors in 1st-line PD-L1-low gastric cancer. Akeso, Inc.presents findings.

In Hong Kong on January 13, 2026, Akeso, Inc.revealed findings from a real-world analysis at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). The study compared the effectiveness of cadonilimab in combination with chemotherapy to that of a PD-1 inhibitor along with [include more information].

Unusual Whales·
HK
09926
-3.78%
Unusual Whales·
HK
09926
-3.78%
Posts
View More

Another day where biotech stocks stand out in the Hong Kong market $AKESO(09926.HK) sold too early, lacking vision.

  • 0

In my Hong Kong stock watchlist, it's another day for innovative drugs. $AKESO(09926.HK) was sold too soon, missing a 40% gain.

  • 0
© 2026 Longbridge｜Disclaimer